Wang et al. provide another potential mechanism in which RAC1 contributes to HER2+ breast cancer therapy resistance via a mutant HER2/RAC1/JNK/AP1/TGF-β (Transforming growth factor beta) pathway. The gene discussed is ERBB2; the disease is breast carcinoma.